Interpretation of medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline.
10.3760/cma.j.cn112144-20211028-00477
- Author:
Heng CHEN
1
;
Yue HE
1
Author Information
1. Department of Oral & Maxillofacial-Head & Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine & College of Stomatology, Shanghai Jiao Tong University & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Shanghai Key Laboratory of Stomatology, Shanghai 200011, China.
- Publication Type:Journal Article
- MeSH:
Bisphosphonate-Associated Osteonecrosis of the Jaw/therapy*;
Bone Density Conservation Agents/adverse effects*;
Humans;
Jaw;
Medical Oncology;
Neoplasms/drug therapy*;
Osteonecrosis/chemically induced*;
Quality of Life
- From:
Chinese Journal of Stomatology
2022;57(2):128-135
- CountryChina
- Language:Chinese
-
Abstract:
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event related to administration of antiresorptive or antiangiogenic medications. With the increasing usage of bone-modifying agents in cancer therapy, the incidence of MRONJ enhanced gradually, which affects the life quality of patients and interferes with cancer therapy. In 2019, Multinational Association of Supportive Care in Cancer (MASCC), International Society of Oral Oncology (ISOO) and American Society of Clinical Oncology (ASCO) convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations on practices in the prevention and management of MRONJ in patients with cancer. The present article made an interpretation of Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline so as to provide clinicians with diagnostic and therapeutic approaches for cancer patients with MRONJ.
